Fuji Pharma Co., Ltd. (TYO:4554)
Japan
· Delayed Price · Currency is JPY 2,252.00
-94.00 (-4.01%)
Mar 9, 2026, 3:30 PM JST
Fuji Pharma Revenue
Fuji Pharma had revenue of 15.90B JPY in the quarter ending December 31, 2025, with 22.28% growth. This brings the company's revenue in the last twelve months to 54.57B, up 12.77% year-over-year. In the fiscal year ending September 30, 2025, Fuji Pharma had annual revenue of 51.68B with 12.01% growth.
Revenue (ttm)
54.57B
Revenue Growth
+12.77%
P/S Ratio
1.01
Revenue / Employee
31.01M
Employees
1,760
Market Cap
55.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 51.68B | 5.54B | 12.01% |
| Sep 30, 2024 | 46.14B | 5.25B | 12.84% |
| Sep 30, 2023 | 40.89B | 5.46B | 15.42% |
| Sep 30, 2022 | 35.43B | 1.44B | 4.22% |
| Sep 30, 2021 | 33.99B | 197.00M | 0.58% |
| Sep 30, 2020 | Pro | Pro | Pro |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ASKA Pharmaceutical Holdings | 68.70B |
| Daito Pharmaceutical | 51.20B |
| Koa Shoji Holdings | 23.66B |
| Mizuho Medy | 11.26B |
| Zeria Pharmaceutical | 86.61B |
| KYORIN Pharmaceutical | 133.26B |
| Mochida Pharmaceutical | 111.92B |
| Fuso Pharmaceutical Industries,Ltd. | 62.17B |
Fuji Pharma News
- 6 months ago - Alvotech Receives Marketing Approval In Japan For Three New Biosimilars - Nasdaq
- 9 months ago - Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility - Benzinga
- 1 year ago - Olic anticipates buoyant demand for contraceptives - Bangkok Post